Longitudinal ctDNA analysis using a high-sensitivity tumor-informed assay in this study revealed valuable insights into ctDNA dynamics and timing in patients with HR+/HER2−negative MBC undergoing standard endocrine and CDK4/6i therapy. This evidence concerns the gene CDK4 and neoplasm.